Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
Capital expenditures decreased by 84% from FY24 to FY25.
Current Price
$74.81
+1.81%Arrowhead Pharmaceuticals Inc (ARWR) Insider Trades
ARWR Insider Trading Activity
Track insider trading transactions for Arrowhead Pharmaceuticals Inc (ARWR). Monitor recent buys, sells, and option exercises by officers, directors, and 10% beneficial owners. Insider trading activity can signal management confidence or concern about a stock's future prospects.
Current stock price: $74.81. Market cap: $10.16B. This page displays the most recent insider transactions for ARWR, including the insider's name, title, transaction type (purchase, sale, or option exercise), number of shares, and total value. Filter transactions by type to focus on open-market purchases or sales.
Insider buying is often viewed as a bullish signal, as insiders are putting their own capital at risk. Conversely, large insider sales may warrant further investigation. Use GoodMoat's insider trading data alongside financial analysis, quality scores, and valuation tools for a comprehensive view of Arrowhead Pharmaceuticals Inc's investment outlook.